HemoCath is committed to improving care for critically ill patients.
Embedded Files
About HemoCath
About HemoCath
HemoCath pioneers innovations at the intersection of MedTech and Digital Health, committed to improving care for critically ill patients and people living with heart failure.
The scalable HemoCath™ AI Platform seamlessly integrates the HemoCath™ PA catheter securely connected to the Swan™ AI Cloud, providing continuous monitoring and proactive AI-driven management of critically ill patients.
Engineered for simplicity, the Platform supports diagnosis, treatment, and monitoring across all hospital-based heart procedures, enabling optimized guideline-directed medical therapy (GDMT). Clinical trials have demonstrated significant advancements in cardiac care and reductions in hospital stays through pulmonary artery pressure-guided heart failure management.
Leadership Team
Leadership Team
Our leadership team has over 100 years of combined experience in medical devices, engineering, commercialization, and corporate finance, with a proven track record in product development, business strategy, and successfully bringing innovations to market.
Eric Caron
Chief Executive Officer, Co-Founder
Eric Caron
Chief Executive Officer, Co-Founder
Experienced entrepreneur and engineer with a strong background in medical devices, digital health, and high-tech industries. Demonstrated success in leading ventures from concept to commercialization and exit. With over 25 years of industry and leadership experience, Eric has held key roles across engineering R&D, product development, manufacturing, commercialization, finance, sales, and marketing. He holds a Bachelor’s degree in Engineering and an MBA.
Des Regan
Chief Technology Officer, Co-Founder
Des Regan
Chief Technology Officer, Co-Founder
Des Regan is an expert in engineering development of novel medical devices, with an impressive track record over the past 30 years. He founded and lead a number of startup companies developing medical devices in Ireland. Des has been Director of Product Development since 2003 with established companies such as Nordson Medical, Phillips Medisize and Medtronic. Inventor on 23 patents in the medical field. He holds a BS and MS in mechanical engineering.
Christopher Glover, MD, FRCPC
Chief Medical Officer
Christopher Glover, MD, FRCPC
Chief Medical Officer
Dr. Christopher Glover is Interventional Cardiologist and Director of Cardiac Catheterization at the University of Ottawa Heart Institute. Dr. Glover is also Associate Professor and Director of Education and Clinical Services in the division of cardiology at the University of Ottawa. With over 25 years of experience as an interventional cardiologist, he has developed extensive expertise in cardiac diseases and transcatheter valve replacements.
Robert Orr
Chief Financial Officer, Board Member
Robert Orr
Chief Financial Officer, Board Member
Seasoned corporate development strategist with 20 years of public practice with M&A at PwC and Deloitte. Chartered Professional Accountant, Chartered Business Valuators and senior member of American Society of Appraiser with a specialty in business valuation. Since 2010, co-founder & CEO of Life360 Innovations, commercializing a medical device for men with urinary incontinence. In addition, a board member and advisor for a number of companies.
The Inspiring Irish Legacy of Dr. Jeremy Swan
The Inspiring Irish Legacy of Dr. Jeremy Swan
Born in Sligo, Ireland, Dr. Jeremy Swan was the son of two Irish doctors. He received his education at Glenstal Abbey School in Limerick and Castleknock College in Dublin. As a young student, he overcame life-threatening meningitis. He studied medicine at St. Thomas’ Hospital in London. Following his service as a physician in the Royal Air Force, he became a distinguished researcher in cardiovascular physiology.
Dr. Swan made revolutionary contributions to cardiology. In 1968, he co-invented the Swan-Ganz pulmonary artery catheter, a groundbreaking innovation that revolutionized heart monitoring and became a vital standard tool in critical care and heart surgery worldwide. As director of cardiology at Cedars-Sinai Medical Center in Los Angeles for over two decades, he played a pivotal role in shaping interventional cardiology and mentoring future generations of physicians.
Dr. Swan’s remarkable contributions were recognized with numerous international honors, including an honorary doctorate from Trinity College Dublin. His legacy continues to inspire advancements in medical technology and patient care globally.
Our Mission
Our Mission
At HemoCath, we are dedicated to advancing critical care with the next generation of pulmonary artery catheters. Our mission is to enhance patient outcomes through innovative, precise, and reliable hemodynamic monitoring solutions. Inspired by Dr. Jeremy Swan’s legacy of innovation, we strive to empower healthcare professionals with cutting-edge medical technology that improves decision-making, optimizes treatment, and sets new standards in cardiovascular care.
Page updated
Report abuse